✦ LIBER ✦

Zoledronic acid (ZA) prevents aromatase inhibitor (Al)-associated bone loss in postmenopausal women with early breast cancer -36-month follow-up of the Z-FAST study

✍ Scribed by A. Brufskv; L. Bosserman; R. Caradonna; B. Haley; M. Jones; H. Moore; M. Dong; G. Warsi; S. Ericson; E. Perez

Book ID: 119598302
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)70810-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Zoledronic Acid Effectively Prevents Aro

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

✍ Adam M. Brufsky; Linda D. Bosserman; Richard R. Caradonna; Barbara B. Haley; C. 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 151 KB

P154 Twenty-four month follow-up of the

P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ A. Brufsky; K. Lund; S. Papish; P. Cobb; P. Eisenberg; M. Dong; G. Warsi; L. Lac 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Immediate Administration of Zoledronic A

Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial

✍ Antonio Llombart; Antonio Frassoldati; Outi Paija; Harm Peter Sleeboom; Guy Jeru 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 437 KB

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

2008 POSTER The E-ZO-FAST trial: Zoledro

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

✍ N. Schenk; A. Lombart; A. Frassoladti; P. Neven; G. Jerusalem; I. Deleu; J. Mebi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 84 KB

P153 An integrated analysis of zoledroni

P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ A. Brufsky; N. Bundred; R. Coleman; R. Lambert-Falls; R. Mena; M. Dong; N. Schen 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB